Catalog |
name |
Description |
price |
R-R-2950 |
Plecanatide acetate CAS No.1075732-84-1 |
Plecanatide acetate/CAS No.1075732-84-1, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis. |
price> |
R-R-2951 |
MM 419447 CAS No.1092457-78-7 |
MM 419447/CAS No.1092457-78-7, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C). |
price> |
R-R-2952 |
CFM 1571 hydrochloride CAS No.1215548-30-3 |
CFM 1571 hydrochloride/CAS No.1215548-30-3 is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases. |
price> |
R-R-2953 |
Dolcanatide CAS No.1092457-65-2 |
Dolcanatide/CAS No.1092457-65-2 is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research. |
price> |
R-R-2954 |
Guanylin(human) TFA |
Guanylin(human) TFA, a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) TFA is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism. |
price> |
R-R-2955 |
Ebselen oxide CAS No.104473-83-8 |
Ebselen oxide/CAS No.104473-83-8, the selenone analogue of Ebselen, covalently modifies diguanylate cyclase (DGC) to inhibit c-di-GMP-receptor interactions and reduces DGC activity. Ebselen oxide also inhibits alginate production (IC50=14 μM) by Pseudomonas aeruginosa. Ebselen oxide inhibits HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 (IC50 ranging from 0.2 to 4.7 μM). |
price> |
R-C-1256 |
Rimonabant CAS:168273-06-1 |
Rimonabant(SR141716)is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.Rimonabant is also a dual inhibitor of acyl CoA:cholesterol acyltransferases(ACAT)1 and 2 and inhibits mycobacterial MmpL3. |
price> |
R-R-2956 |
Cysmethynil CAS No.851636-83-4 |
Cysmethynil/CAS No.851636-83-4 is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research. |
price> |
R-R-2958 |
Sotorasib CAS No.2296729-00-3 |
Sotorasib (AMG-510)/CAS No.2296729-00-3 is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors. |
price> |
R-R-2959 |
MRTX1133 CAS No.2621928-55-8 |
MRTX1133/CAS No.2621928-55-8 is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations. |
price> |